CytomX Therapeutics, Inc.

CytomX Therapeutics Beats on EPS, Stock Up 2.38%

CytomX Therapeutics reported a smaller-than-expected loss per share, which pleased investors and led to a 2.38% increase in stock price. However, there was no revenue reported or guidance provided, leaving some uncertainty about the company's future performance. The positive EPS surprise indicates potential operational improvements, but the lack of additional context from management limits a deeper understanding of the company's direction.